Back to search results

Personalizing Blood Clot Prevention for Peripheral Artery Disease

This study is looking at whether a personalized plan for preventing blood clots works better than standard treatment for adults with peripheral artery disease (PAD). PAD affects blood flow to your legs. Participants in this study have had a procedure to restore blood flow to their legs. Researchers will compare a personalized plan, which uses a blood test called Thromboelastography with Platelet Mapping (TEG-PM) to choose your medication, against standard treatments. Standard treatments include combinations of Aspirin, Clopidogrel, Ticagrelor, and Rivaroxaban. The main goal is to see if the personalized plan lowers the number of blood clots in the treated leg one year after the procedure. It also aims to see if it reduces amputations, repeat procedures, bleeding, and death. About 484 people are expected to join this study. The current recruitment status is unclear.

Study design
This is an interventional study comparing a personalized treatment plan to standard care. It plans to enroll 484 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after their revascularization procedure to check for arterial thrombosis in the treated limb.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07613840

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Recruiting
NAAges 18+InterventionalTreatment
Massachusetts General Hospital
~484 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:AspirinClopidogrelTicagrelorRivaroxabanThromboelastography with Platelet Mapping

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Arterial Thrombosis in the Treated Limb
Measured over 12 months post-revascularization

Conditions

Peripheral Arterial Disease (PAD)
Amputation
Thrombosis
Thrombosis (Stent Thrombosis)
Platelet Aggregation Inhibitors
Thromboelastography (TEG)
PRU(Platelet Reactivity Unit)

Explore related trials

Peripheral Artery Disease

Where it's being run

2 sites across 1 states
Massachusetts2

Who to contact

Anahita Dua, MBCHB, MBA, MSC
[email protected]
262-565-8247
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization.
Patients at the age of 18 or older

Exclusion

Patients who are younger than 18 years old
Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
Prisoners, defined as those who have been directly admitted from a correctional facility.
No atherosclerosis
Subject has active stomach ulcers
Subject has severe hepatic impairment
Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \>1 year, the study team will consult with the

What this trial measures

  • Incidence of Arterial Thrombosis in the Treated Limb12 months post-revascularization

    Proportion of participants experiencing graft or stent thrombosis in the revascularized limb, compared between the TARGET and SOC arms. Thrombosis will be assessed via vascular studies including ankle-brachial index, arterial duplex, and toe pressure at scheduled follow-up visits.